CoChat
Sign Up
Cited by 17

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Statins and Lp(a): The plot thickens

Enkhmaa, Byambaa, Berglund, Lars·2019·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2019.07.021PMC PMC7098730
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2019.07.021

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Statins versus PCSK9 inhibitors: Effects on LDL-C and Lp(a) Both statins and PCSK9 inhibitors reduce LDL-C levels through mechanisms involving LDL receptor upregulation. In contrast, while PCSK9 inhibitors reduce Lp(a) levels, statins may increase Lp(a) levels. PCSK9-induced Lp(a) reduction maybe facilitated by markedly reduced competition from LDL-C for binding to LDL receptor and/or reduced production of apo(a) among patients taking PCSK9 inhibitors. On the other hand, increased production of apo(a), primarily of small sizes, may contribute to statin-induced Lp(a) elevation.
Figure 1. Statins versus PCSK9 inhibitors: Effects on LDL-C and Lp(a) Both statins and PCSK9 inhibitors reduce LDL-C levels through mechanisms involving LDL receptor upregulation. In contrast, while PCSK9 inhibitors reduce Lp(a) levels, statins may increase Lp(a) levels. PCSK9-induced Lp(a) reduction maybe facilitated by markedly reduced competition from LDL-C for binding to LDL receptor and/or reduced production of apo(a) among patients taking PCSK9 inhibitors. On the other hand, increased production of apo(a), primarily of small sizes, may contribute to statin-induced Lp(a) elevation.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 18

  1. Cheesman, 2000, An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a), J. Biol. Chem., 275, 28195, 10.1074/jbc.M002772200 · DOI
  2. Reyhana Yahya, 2019, Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype, Atherosclerosis, 201, 10.1016/j.atherosclerosis.2019.07.001 · DOI
  3. Kostner, 1989, HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels, Circulation, 80, 1313, 10.1161/01.CIR.80.5.1313 · DOI
  4. Hunninghake, 1993, Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein(a), J. Clin. Pharmacol., 33, 574, 10.1002/j.1552-4604.1993.tb04706.x · DOI
  5. Haffner, 1995, Effect of simvastatin on Lp(a) concentrations, Clin. Cardiol., 18, 261, 10.1002/clc.4960180507 · DOI
  6. Fieseler, 1991, Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation, Clin. Chim. Acta, 204, 291, 10.1016/0009-8981(91)90239-9 · DOI
  7. van Wissen, 2003, Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia, Heart, 89, 893, 10.1136/heart.89.8.893 · DOI · Paper page
  8. Willeit, 2018, Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials, Lancet, 392, 1311, 10.1016/S0140-6736(18)31652-0 · DOI · Paper page
  9. Sahebkar, 2017, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials, BMC Med., 15, 22, 10.1186/s12916-017-0787-7 · DOI
  10. Tsimikas, 2019, Statin therapy increases lipoprotein(a) levels, Eur. Heart J., 0, 1
  11. Klausen, 1993, Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration, Eur. J. Clin. Investig., 23, 240, 10.1111/j.1365-2362.1993.tb00768.x · DOI
  12. Ginsberg, 1998, Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, Protocol 1, Arterioscler. Thromb. Vasc. Biol., 18, 441, 10.1161/01.ATV.18.3.441 · DOI
  13. Silaste, 2004, Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a), Arterioscler. Thromb. Vasc. Biol., 24, 498, 10.1161/01.ATV.0000118012.64932.f4 · DOI
  14. Enkhmaa, 2017, The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab, J. Lipid Res., 58, 2008, 10.1194/jlr.M078212 · DOI
  15. Romagnuolo, 2015, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor, J. Biol. Chem., 290, 11649, 10.1074/jbc.M114.611988 · DOI · Paper page
  16. Watts, 2017, Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism, Circulation, 135, 338, 10.1161/CIRCULATIONAHA.116.025080 · DOI · Paper page
  17. Scanu, 2002, Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels, Lipids, 37, 439, 10.1007/s11745-002-0915-1 · DOI
  18. Grundy, 2019, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines, J. Am. Coll. Cardiol., 73, 3168, 10.1016/j.jacc.2018.11.002 · DOI · Paper page

Cited by

Sorted by citations

See all 17

Metadata

Authors
Enkhmaa, B., & Berglund, L.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2019-10
Volume
289
Pages
173-175
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2019.07.021
PMC
PMC7098730
Cited by
17
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • UC Davis Clinical and Translational Science Center (UL1 TR001860)
  • NIH Building Interdisciplinary Research Careers in Women’s Health/K12 Program (2K12HD051958)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statins and Lp(a): The plot thickens. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2019.07.021
The paper
Enkhmaa, B., & Berglund, L. (2019). Statins and Lp(a): The plot thickens. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2019.07.021